Mendus AB (publ)
Research Mendus AB (publ) (IMMU) on Bullrun: market cap SEK 436.55M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMMU
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 436.55M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 21.02M
- Free cash flow-SEK 20.80M
Valuation Snapshot
latest market cap is SEK 436.55M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 113.26M | -SEK 81.84M | n/a | -2.17 | SEK 64.66M | SEK 18.85M | SEK 585.07M |
| FY2022 | SEK 3.38M | -SEK 138.79M | -SEK 121.43M | n/a | -0.7 | SEK 41.85M | SEK 52.04M | SEK 514.44M |
| FY2021 | SEK 31.00K | -SEK 133.41M | -SEK 139.39M | n/a | -0.73 | SEK 155.31M | SEK 36.67M | SEK 656.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 436.55M | n/a | n/a | n/a |
About Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mendus AB (publ)'s market cap?
Mendus AB (publ)'s market capitalization is SEK 436.55M.
What does Mendus AB (publ) do?
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel.